How to Navigate Ecosystem Connect NEWDistinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats
A Phase I Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination with L19-IL2 As a Treatment of Metastatic FAP-positive Solid Tumors
Description:
The aim of this study is to assess the safety of [177Lu]Lu-OncoFAP-23 alone or in combination with L19-IL2 for the treatment of advanced/metastatic Fibroblast Activation Protein (FAP)-positive solid tumors and to establish a Recommended Dose (RD).
Sponsor:
Philogen S.p.A.
Government Study Link:
NCT06640413 - Click here to see study onClinicalTrials.gov
[177Lu]Lu-OncoFAP-23
Isotope(s):
Target(s):
- FAP
Ligand: Small Molecules
Chelator: DOTAGA
